Grifols Secures 95% of Investor Support to Improve Documentation Terms of Its €1.3 Billion 7.5% Secured Notes

Barcelona, November 12, 2025. Grifols, S.A. (MCE: GRF, NASDAQ: GRFS), a global leader in plasma-derived medicines and innovative healthcare solutions, today announced that almost the 95% of bond investors holding its €1.3 billion 7.5% Senior Secured Notes due 2030 have approved the proposed amendment to the notes’ indenture, exceeding the required majority well ahead of the deadline.

The strong level of support follows the company’s recent consent solicitation process, which sought approval to align certain provisions of the 7.5% Notes and the Indenture with those governing the Company’s more recently issued 7.125% Senior Secured Notes due 2030, ensuring greater consistency across its capital structure and enhancing the company’s overall financial flexibility.

Rahul Srinivasan, CFO of Grifols, said: “The successful bondholder consent solicitation exercise not only further validates institutional investors’ strong confidence in Grifols but, importantly, also increases Grifols’ flexibility with regards to the refinancing plans we referenced in our Q3 results presentation.”